This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Simulations Plus, Inc. designs and develops pharmaceutical simulation software for use in pharmaceutical research, and in the education of pharmacy and medical students.View SLP key stats
Simulations Plus, Inc. - SLP - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Simulations Plus, Inc. as a
Buy with a ratings score of B+.
Report Snippet: We rate SIMULATIONS PLUS INC (SLP) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.